We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

107 hedge funds and large institutions have $281M invested in Pacific Biosciences in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

1% more funds holding

Funds holding: 106 → 107 (+1)

0.05% more ownership

Funds ownership: 70.92% → 70.97% (+0.05%)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

31% less capital invested

Capital invested by funds: $406M → $281M (-$125M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

99% less call options, than puts

Call options by funds: $5K | Put options by funds: $722K

Holders
107
Holders Change
+1
Holders Change %
+0.94%
% of All Funds
2.67%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
17
Increased
34
Reduced
38
Closed
16
Calls
$5K
Puts
$722K
Net Calls
-$717K
Net Calls Change
+$3.13M

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$26.6M
2
CCM
Consonance Capital Management
New York
+$15.5M
3
OIM
Oracle Investment Management
Connecticut
+$11.1M
4
MC
Maverick Capital
Texas
+$6.17M
5
FCM
Frontier Capital Management
Massachusetts
+$6.07M

Top Sellers

1
Credit Agricole
Credit Agricole
France
-$77.8M
2
GGHC
Gilder Gagnon Howe & Co
New York
-$10M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.61M
4
Morgan Stanley
Morgan Stanley
New York
-$2.71M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$2.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$1.51M -$193K -47,938 -10%
PP
27
PDT Partners
New York
$1.41M +$590K +146,423 +59%
Fuller & Thaler Asset Management
28
Fuller & Thaler Asset Management
California
$1.38M -$6.05K -1,500 -0.4%
SIM
29
Spark Investment Management
New York
$1.35M +$1.53M +379,800 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.33M -$140K -34,755 -9%
CC
31
Casdin Capital
New York
$1.07M -$1.61M -400,000 -57%
MIM
32
Monashee Investment Management
Massachusetts
$1.07M +$1.21M +300,000 New
SI
33
Stephens Inc
Arkansas
$1.01M +$25.3K +6,274 +2%
Charles Schwab
34
Charles Schwab
California
$984K -$313K -77,558 -22%
UM
35
Ulysses Management
New York
$918K – – –
EIM
36
Essex Investment Management
Massachusetts
$901K +$414K +102,640 +68%
Deutsche Bank
37
Deutsche Bank
Germany
$794K -$447K -110,735 -33%
TCIM
38
TIAA CREF Investment Management
New York
$783K +$36.5K +9,062 +4%
BLAM
39
Bourne Lent Asset Management
New York
$706K -$18.1K -4,500 -2%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$639K -$299K -74,075 -29%
Swiss National Bank
41
Swiss National Bank
Switzerland
$600K +$121K +30,000 +22%
Goldman Sachs
42
Goldman Sachs
New York
$534K +$118K +29,192 +24%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$529K -$38.7K -9,600 -6%
CLOS
44
Compagnie Lombard Odier SCmA
Switzerland
$524K -$89.5K -22,200 -13%
Wells Fargo
45
Wells Fargo
California
$520K -$299K -74,212 -34%
PPA
46
Parametric Portfolio Associates
Washington
$519K -$157K -38,918 -21%
SG Americas Securities
47
SG Americas Securities
New York
$435K +$131K +32,446 +36%
AllianceBernstein
48
AllianceBernstein
Tennessee
$407K +$144K +35,700 +45%
UBS Group
49
UBS Group
Switzerland
$403K -$1.07K -266 -0.2%
WMSA
50
Weiss Multi-Strategy Advisers
New York
$379K -$2.02K -500 -0.5%
1
2
3 4 5

PACB Hedge Fund Activity: Q2 2017 in Review

107 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2017, worth a combined $281M — down 31% from $406M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PACB positions and 16 closed out — a net gain of 1 holder — while 34 added to existing stakes and 38 trimmed.

The largest buyer was Capital World Investors, adding an estimated $26.6M. The largest seller was Credit Agricole, exiting entirely with an estimated $77.8M sold.

  • 107 institutional investors held Pacific Biosciences (PACB) as of Q2 2017, up from 106 in Q1 2017.
  • Funds reported $281M of Pacific Biosciences stock for Q2 2017, down 31% quarter-over-quarter.
  • 17 funds opened new Pacific Biosciences positions in Q2 2017 and 16 closed out, a net change of +1 holder.
  • The largest Pacific Biosciences buyer in Q2 2017 was Capital World Investors, an estimated $26.6M added.
  • The largest Pacific Biosciences seller in Q2 2017 was Credit Agricole, an estimated $77.8M sold.

Based on aggregated 13F filings for Q2 2017.